The global plasma fractionation sector was valued at USD 37.87 billion in 2025 and is expected to reach USD 40.73 billion in 2026. It is projected to grow to around USD 78.34 billion by 2035, expanding at a CAGR of 7.54% from 2026 to 2035. Rising demand for plasma-derived therapies, growing cases of immune and coagulation disorders, and advances in plasma processing are supporting this growth.
What Is Plasma Fractionation?
Plasma fractionation is a process used to separate blood plasma into valuable proteins such as albumin, immunoglobulins, coagulation factors, and fibrinogen. These components are used to develop therapies for conditions including immune deficiencies, bleeding disorders, autoimmune diseases, and neurological disorders.
Key Trends
One major trend is the growing use of chromatography-based separation. This technology can improve protein purity and help manufacturers isolate delicate proteins more efficiently, supporting the development of new plasma-derived therapies.
Demand for immunoglobulins is also increasing as these products are widely used to support patients who cannot produce sufficient antibodies. In 2025, the immune globulin segment dominated by type, while coagulation factors are expected to see strong growth as demand for treatments that control bleeding increases.
Hospitals remained the leading application segment because plasma-derived products are widely used in emergency care and the treatment of immune and blood-related disorders. Retail pharmacies are also expected to expand as more therapies become available for outpatient and home-based treatment.
Regional Outlook
North America held the largest share in 2025, supported by strong plasma collection networks, advanced healthcare infrastructure, and the presence of major companies. The United States remains a major source of plasma for fractionation.
Europe is expected to grow rapidly, with governments focusing on strengthening domestic plasma supplies and reducing dependence on external sources. The UK, for example, has initiatives aimed at increasing plasma collection and ensuring a stable supply of plasma-derived medicines.
Asia-Pacific is also gaining attention as healthcare infrastructure improves and demand for advanced treatments rises.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/5320
Future Outlook
The future of plasma fractionation will depend on reliable plasma collection, improved purification technologies, and growing demand for plasma-derived therapies. Investments in processing facilities and advances in manufacturing are expected to improve supply capacity and support wider access to these essential treatments.
With rising healthcare needs and continued technological progress, plasma fractionation is becoming increasingly important for producing life-saving therapies worldwide.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium